Economy will remain in 'tricky' spot until trade clarity comes, says PGIM's Porcelli
Stephen Parker, JPMorgan co-head of global investment strategy, and Tom Porcelli, PGIM chief U.S. economist, join 'The Exchange' to discuss the latest economic data to cross the tape, how the economy will perform, and much more.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the 13 Biotech Stocks with Huge Upside Potential. Tessa Romero, an analyst at JPMorgan, has maintained her Overweight rating on Cytokinetics, Incorporated (NASDAQ:CYTK) but reduced the firm's price objective from $71 to $53. A lab technician using a microscope to examine the biopharmaceutical company's molecules. Aficamten's revised revenue projections, which anticipate a slower launch trajectory, are the basis for the modification. The management's latest remarks, which reflect the Camzyos launch pace for obstructive hypertrophic cardiomyopathy (oHCM), are consistent with this reevaluation. According to JPMorgan, expectations for adoption will be significantly influenced by the final medicine label. Cytokinetics, Incorporated (NASDAQ:CYTK) experimental treatment for oHCM, Aficamten, is still a valuable tool with promising clinical outcomes. Although JPMorgan admits that the launch trajectory was slower than anticipated, the company is still confident in the drug's unique profile when compared to Camzyos, especially with regard to pharmacology, safety, and dosing flexibility. These qualities and corroborating evidence support JPMorgan's assessment of aficamten's acceptability. The lower price objective is not a reflection of a shift in opinion about the drug's strategic worth or efficacy, but rather of modified commercial ramp assumptions. It is a late-stage biopharmaceutical business that focuses on discovering, developing, and bringing to market first-in-class muscle activators and next-in-class muscle inhibitors as possible cures for fatal diseases where muscle function is impaired or deteriorating. While we acknowledge the potential of CYTK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
JPMorgan Calls the Selloff Excessive, Trims Regeneron Pharmaceuticals, Inc. (REGN) Price Target
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) after reducing its price objective from $950 to $800. A pharmacist in a lab coat carefully analyzing a vial of medicine for its quality. Following poor IL-33 data in late May, the company believes that the recent selloff in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) shares is 'very much overdone.' JPMorgan pointed out that IL-33 was never a key component of its model, though. The company stressed that, even without accounting for any pipeline contribution, Dupixent, Eylea, and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)' solid cash position alone warrants a valuation far higher than current levels. JPMorgan anticipates several catalysts over the next six months that will help reset its value. Recently, the firm's valuation was under pressure due to its IL-33 program's lackluster Phase results. JPMorgan is still optimistic in spite of this, concentrating on important assets like Dupixent and Eylea that support the company's financial stability. The company's updated $800 estimate, which reflects confidence in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)'s core business and future potential milestones, still suggests significant upside. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) discovers, develops, and commercializes drugs to treat eye disease, cardiovascular disease, cancer, and inflammation. It is one of the stocks with huge upside potential. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
JPMorgan Warns Junior Bankers of Termination Over Early Job Offers Amid Talent War
JPMorgan Chase & Co. (NYSE:JPM) is one of the best Dow stocks to invest in. In one of the recent developments, the company is tightening rules for junior employees taking other jobs while still employed at the bank, according to a leaked email. Private equity firms often offer positions up to two years before the start date, leading many recent graduates to pursue these lucrative roles before or during their time as investment banking analysts at firms like JPMorgan Chase & Co. (NYSE:JPM). Now, JPMorgan is warning new US analysts that accepting a future job offer within 18 months of starting at the bank could result in termination. This policy aims to prevent any "potential conflicts of interest" and preserve client trust. The memo also notes that analysts could be fired for missing onboarding or summer training sessions. JPMorgan Chase & Co. (NYSE:JPM) CEO Jamie Dimon called out the issue of losing talent to private equity last year, labeling it "unethical." He explained that job hopping to private equity puts the bank in a difficult spot since analysts might already be committed elsewhere while handling sensitive information at JPMorgan. While we acknowledge the potential of JPM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None.
